Avidity Partners Management LP
DALLAS, TX
$624m in 45 US stocks at the end of 30 June 2026. The top 10 are 81.9% of the money. It changed about 19.9% of the portfolio this quarter.
Value
$624m
Stocks
45
Top 10 share
81.9%
Turnover
19.9%
What changed this quarter
New
Bought for the first time this quarter.
- Mobia MedicalMOBI1.7% of the fund
- ImmunicIMUX1.6% of the fund
- Senseonics HoldingsSENS1.5% of the fund
- Nuvectis PharmaNVCT0.6% of the fund
- Alamar BiosciencesALMR0.5% of the fund
- Avalyn PharmaAVLN0.3% of the fund
- Kailera TherapeuticsKLRA0.3% of the fund
- ScynexisSCYX0.2% of the fund
- EvommuneEVMN0.2% of the fund
Added
Bought more of a stock they already held.
- CG OncologyCGON15.9% of the fund+9%
- Tempus AITEM1.0% of the fund+17%
- Structure TherapeuticsGPCR0.8% of the fund+26%
- InsuletPODD0.6% of the fund+140%
Cut
Sold some of their stake.
- Dianthus TherapeuticsDNTH32.8% of the fund-50%
- Oruka TherapeuticsORKA11.6% of the fund-50%
- Jade BiosciencesJBIO6.1% of the fund-39%
- Enliven TherapeuticsELVN4.5% of the fund-31%
- Perspective TherapeuticsCATX3.4% of the fund-48%
- Aktis OncologyAKTS2.5% of the fund-48%
- Palvella TherapeuticsPVLA1.7% of the fund-50%
- RepligenRGEN1.7% of the fund-50%
- Teva Pharmaceutical IndustriesTEVA1.1% of the fund-69%
- DexcomDXCM1.1% of the fund-47%
- MedtronicMDT0.9% of the fund-65%
- Vir BiotechnologyVIR0.8% of the fund-67%
- Encompass HealthEHC0.7% of the fund-50%
- Tenax TherapeuticsTENX0.6% of the fund-45%
- Boston ScientificBSX0.5% of the fund-33%
- Satellos BioscienceMSLE0.5% of the fund-50%
- Context TherapeuticsCNTX0.4% of the fund-50%
- Gilead SciencesGILD0.4% of the fund-50%
- Phathom PharmaceuticalsPHAT0.3% of the fund-60%
- Genmab A/SGMAB0.2% of the fund-50%
- Intellia TherapeuticsNTLA0.2% of the fund-50%
- Corvus PharmaceuticalsCRVS0.2% of the fund-65%
- Oddity TechODD0.2% of the fund-50%
- Peloton InteractivePTON<0.1% of the fund-75%
- BridgeBio Oncology TherapeuticsBBOT<0.1% of the fund-50%
Sold out
Sold their entire stake.
- ImmunicIMUX-100%
- HumanaHUM-100%
- Scynexis-100%
- IconICLR-100%
- NateraNTRA-100%
- Hims & Hers HealthHIMS-100%
- Corcept TherapeuticsCORT-100%
- CenteneCNC-100%
- Anteris Technologies GlobalAVR-100%
- MoonLake ImmunotherapeuticsMLTX-100%
- KenvueKVUE-100%
- Revolution MedicinesRVMD-100%
- Abivax SAABVX-100%
- Arbutus BiopharmaABUS-100%
- UnitedHealth GroupUNH-100%
- Acadia PharmaceuticalsACAD-100%
Holdings
- Mobia MedicalMOBI
- Share
- 1.7%
- Value
- $11m
- Shares
- 798,282
New
- Structure TherapeuticsGPCR
- Share
- 0.8%
- Value
- $5m
- Shares
- 98,000
+26%
- Satellos BioscienceMSLE
- Share
- 0.5%
- Value
- $3m
- Shares
- 387,769
-50%
- Alamar BiosciencesALMR
- Share
- 0.5%
- Value
- $3m
- Shares
- 110,000
New
- Avalyn PharmaAVLN
- Share
- 0.3%
- Value
- $2m
- Shares
- 60,000
New
- Kailera TherapeuticsKLRA
- Share
- 0.3%
- Value
- $2m
- Shares
- 80,000
New
- Genmab A/SGMAB
- Share
- 0.2%
- Value
- $1m
- Shares
- 50,000
-50%
- Legend BiotechLEGN
- Share
- <0.1%
- Value
- $433,200
- Shares
- 15,000
Held
| Company | Share of fund | Value | Shares | Change |
|---|---|---|---|---|
| Dianthus TherapeuticsDNTH | 32.8% | $205m | 2,104,184 | -50% |
| CG OncologyCGON | 15.9% | $99m | 1,398,948 | +9% |
| Oruka TherapeuticsORKA | 11.6% | $72m | 760,424 | -50% |
| Jade BiosciencesJBIO | 6.1% | $38m | 1,700,708 | -39% |
| Enliven TherapeuticsELVN | 4.5% | $28m | 550,000 | -31% |
| Perspective TherapeuticsCATX | 3.4% | $21m | 6,299,999 | -48% |
| Aktis OncologyAKTS | 2.5% | $16m | 484,200 | -48% |
| Palvella TherapeuticsPVLA | 1.7% | $11m | 70,000 | -50% |
| Mobia MedicalMOBI | 1.7% | $11m | 798,282 | New |
| RepligenRGEN | 1.7% | $11m | 77,800 | -50% |
| ImmunicIMUX | 1.6% | $10m | 669,941 | New |
| Senseonics HoldingsSENS | 1.5% | $9m | 1,600,000 | New |
| Karyopharm TherapeuticsKPTI | 1.4% | $9m | 924,487 | Held |
| Teva Pharmaceutical IndustriesTEVA | 1.1% | $7m | 200,000 | -69% |
| DexcomDXCM | 1.1% | $7m | 100,000 | -47% |
| Tempus AITEM | 1.0% | $6m | 105,000 | +17% |
| MedtronicMDT | 0.9% | $5m | 70,000 | -65% |
| Vir BiotechnologyVIR | 0.8% | $5m | 519,300 | -67% |
| Structure TherapeuticsGPCR | 0.8% | $5m | 98,000 | +26% |
| Encompass HealthEHC | 0.7% | $4m | 42,000 | -50% |
| Tenax TherapeuticsTENX | 0.6% | $4m | 265,934 | -45% |
| Nuvectis PharmaNVCT | 0.6% | $4m | 200,000 | New |
| InsuletPODD | 0.6% | $4m | 24,000 | +140% |
| Boston ScientificBSX | 0.5% | $3m | 80,000 | -33% |
| Satellos BioscienceMSLE | 0.5% | $3m | 387,769 | -50% |
| Alamar BiosciencesALMR | 0.5% | $3m | 110,000 | New |
| Context TherapeuticsCNTX | 0.4% | $3m | 4,998,267 | -50% |
| Gilead SciencesGILD | 0.4% | $3m | 20,000 | -50% |
| Charles River Laboratories InternationalCRL | 0.4% | $2m | 10,000 | Held |
| Phathom PharmaceuticalsPHAT | 0.3% | $2m | 200,000 | -60% |
| Avalyn PharmaAVLN | 0.3% | $2m | 60,000 | New |
| Kailera TherapeuticsKLRA | 0.3% | $2m | 80,000 | New |
| Genmab A/SGMAB | 0.2% | $1m | 50,000 | -50% |
| Intellia TherapeuticsNTLA | 0.2% | $1m | 75,000 | -50% |
| Corvus PharmaceuticalsCRVS | 0.2% | $1m | 80,000 | -65% |
| Oddity TechODD | 0.2% | $1m | 70,000 | -50% |
| ScynexisSCYX | 0.2% | $1m | 260,206 | New |
| EvommuneEVMN | 0.2% | $996,750 | 75,000 | New |
| Abbott LaboratoriesABT | 0.1% | $907,400 | 10,000 | Held |
| BridgeBio PharmaBBIO | 0.1% | $744,800 | 10,000 | Held |
| Peloton InteractivePTON | <0.1% | $591,000 | 100,000 | -75% |
| Legend BiotechLEGN | <0.1% | $433,200 | 15,000 | Held |
| BridgeBio Oncology TherapeuticsBBOT | <0.1% | $334,160 | 43,853 | -50% |
| SavaraSVRA | <0.1% | $308,000 | 50,000 | Held |
| Trevi TherapeuticsTRVI | <0.1% | $124,209 | 6,660 | -50% |
Over time and by industry
Value over time
Jun '25
Dec '25
Jun '26
Value is up 25.2% since 30 June 2025.
Where the money is
Health care96.2%
Industrials1.5%
Technology1.0%
Materials0.2%
Retail & consumer0.1%
Other1.1%
From the fund's 13F filings. They list US stocks and options only, 45 days after each quarter, and leave out cash, bonds, shorts and foreign shares.